Saturday, May 21, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Study discovers potent and selective human monoclonal antibodies against Omicron variant of SARS-CoV-2

by Medical Finance
in Coronavirus
Study: Potent and specific human monoclonal antibodies against SARS-CoV-2 Omicron variant by rapid mRNA immunization of humanized mice. Image Credit: ktsdesign/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

In a recent study posted to the bioRxiv* preprint server, researchers discovered human monoclonal antibodies (mAbs), which were specific and potent against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant.

This was via rapid messenger ribonucleic acid (mRNA) vaccination of humanized mice.

Study: Potent and specific human monoclonal antibodies against SARS-CoV-2 Omicron variant by rapid mRNA immunization of humanized mice. Image Credit: ktsdesign/Shutterstock
Study: Potent and specific human monoclonal antibodies against SARS-CoV-2 Omicron variant by rapid mRNA immunization of humanized mice. Image Credit: ktsdesign/Shutterstock

Background

The SARS-CoV-2 B.1.1.529 (Omicron) variant quickly gained dominance worldwide with its high levels of immune escape and transmissibility. Omicron harbors over 15 mutations in its receptor-binding domain (RBD) relative to the SARS-CoV-2 Wuhan-1 strain.

The existing coronavirus disease 2019 (COVID-19) vaccines are centered on the SARS-COV-2 ancestral strain (Wuhan-1).

Hence, most current SARS-CoV-2 vaccines and mAbs have major reductions in their effectiveness against Omicron due to the numerous mutations in them.

Of note, when existing vaccinations and therapeutic antibodies fail, it’s critical to create next-generation neutralizing mAbs that preserve their efficacy and restrict SARS-CoV-2 viral transmission.

About the study

In the current study, the scientists designed an extremely efficient animal immunization strategy called Rapid mRNA Immunization Of Humanized Mice (RAMIHM) for the development of neutralizing mAbs. The basic idea behind this method was to use high doses of antigen-specific lipid nanoparticle (LNP)-mRNA to immunize immunoglobulin (Ig) humanized mice several times within two weeks to isolate highly efficient neutralizing mAbs against the target antigen.

Further, the team coupled RAMIHM with Omicron-mRNA vaccination in humanized mice and generated three specific and potent clones against the Omicron variant. The clonal repertoires were mapped using customized single-cell B cell receptor (BCR) sequencing (scBCRseq). 

Full-length SARS-CoV-2 Omicron spike (S) sequence employed in mRNA immunization was obtained from two North American Omicron-infected individuals identified on November 23, 2021. The mice were humanized by incorporating human IgK and IgG transgene knock-ins. The mAbs’ binding to Omicron RBD was identified using enzyme-linked immunosorbent assays (ELISA).

Results and discussions

The results showed that RAMIHM led to the derivation of powerful antigen-specific neutralizing mAbs within three weeks. Thus, RAMIHM allowed a quick response towards emerging variants or coronavirus (CoV) species like SARS-CoV and SARS-CoV-2 Delta variants. RAMIHM, unlike other techniques, did not respond to human samples and was completely controllable in the lab.

RAMIHM was quicker than normal immunization and developed entirely human mAbs without the requirement for humanization from standard animal immunization, compared to typical antibody production procedures. In the Omicron-RAMIHM humanized mouse, the scBCRseq data traced clonal repertoires and demonstrated enhanced IgG clonotypes in the plasma B cell, peripheral blood, and memory B cell populations.

RAMIHM found three specific and potent anti-Omicron neutralizing mAbs (MB.08, MB.02, and PC.03) from Ig humanized mice in this investigation. MB.08 had the highest neutralizing and binding capacity against pseudotyped Omicron RBD with a half-maximal inhibitory concentration (IC50) of 44ng/mL. The three clones were more effective than most currently approved clinical mAbs that target SARS-CoV-2 Omicron RBD. Interestingly, the MB.08, MB.02, and PC.03 mAbs did not exhibit any neutralization activity against the SARS-CoV-2 Delta variant, indicating they were selective towards Omicron.

According to the epitope binning results, MB.08 potentially binds to locations in Omicron S RBD that have overlapping epitopes with MB.02 and PC.03. However, when compared to individual clones, an antibody cocktail comprising MB.02 and MB.08 had higher SARS-CoV-2 Omicron neutralizing power with an IC50 of 30 ng/mL. The three leading clones demonstrated competitive angiotensin-converting enzyme 2 (ACE2) binding against the SARS-CoV-2 Omicron RBD. 

Briefly, the MB.08, MB.02, and PC.03 neutralizing mAbs demonstrated a high affinity for Omicron RBD and robust potency in the pseudovirus neutralization experiment. Thus, proving that they were at least twice more potent than current clinically authorized or approved SARS-CoV-2 mAbs, with cocktail combinations enhancing neutralization potency even further.

Conclusions

The study findings indicated that quick mRNA immunization induced robust anti-Omicron antibodies and anti-CoV activity in humanized mice. RAMIHM-scBCRseq revealed top-ranked clones from memory B cell, peripheral blood, and plasma B cell populations with 93.3% Omicron-specificity. Clone screening showed three very effective neutralizing antibodies (MB.08, MB.02, and PC.03) against Omicron. These antibodies exhibited low IC50 values in neutralization and modest nanomolar affinity for Omicron RBD. These features made them more effective than most clinical RBD-targeting mAbs presently approved. 

Overall, the novel animal immunization modality, RAMIHM, developed in the study can potentially act as a flexible platform for antibody development against several therapeutic targets or emerging pathogens. Moreover, the currently discovered fully human mAbs and their cocktail combinations with Omicron-specific action were appropriate for further IND-enabling or translational investigations. 

*Important notice

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:

  • Ping Ren, Lei Peng, Zhenhao Fang, Kazushi Suzuki, Paul A Renauer, Qianqian Lin, Meizhu Bai, Luojia Yang, Tongqing Li, Paul Clark, Daryl Klein, Sidi Chen. (2022). Potent and specific human monoclonal antibodies against SARS-CoV-2 Omicron variant by rapid mRNA immunization of humanized mice. bioRxiv. doi: https://doi.org/10.1101/2022.03.17.484817 https://www.biorxiv.org/content/10.1101/2022.03.17.484817v1.full.pdf+html
Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Active epidemiological investigation on SARS-CoV-2 infection caused by Omicron variant (Pango lineage B.1.1.529) in Japan: preliminary report on infectious period. Image Credit: judyjump/Shutterstock

Study suggests vaccinated Omicron cases are unlikely to shed infectious virus 10 days after diagnosis or symptom onset

by Medical Finance
May 20, 2022
0

Coronavirus disease 2019 (COVID-19) initially emerged in Wuhan, China, and rapidly spread to nearly every country in the world,...

Dog brains can detect speech and show different activity patterns to many languages

Study provides insights into how SARS-CoV-2 impacts the brain

by Medical Finance
May 20, 2022
0

Some patients who develop new cognitive symptoms after a mild bout of COVID have abnormalities in their cerebrospinal fluid similar...

Study: Binding behavior of spike protein and receptor binding domain of the SARS-CoV-2 virus at different environmental conditions. Image Credit: Andrii Vodolazhskyi/Shutterstock

The effect of different environmental conditions on the binding behavior of the S protein and RBD of SARS-CoV-2

by Medical Finance
May 20, 2022
0

In a recent study published in the journal Scientific Reports, a team of researchers investigated the binding behavior of...

Study: A perspective on the applications of furin inhibitors for the treatment of SARS-CoV-2. Image Credit: Sutthituch/Shutterstock

Researchers explore furin inhibitors as a potential tool for treating COVID-19 infection

by Medical Finance
May 20, 2022
0

Furin is a protease enzyme that helps inactive proteins move to a biologically active state. In viruses, furin can cleave...

Study: COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. Image Credit: eamesBot/Shutterstock

Impact of full vaccination with booster doses during periods of different SARS-CoV-2 variant emergence and dominance in the United States

by Medical Finance
May 20, 2022
0

Previous reports indicate that the immunity induced by coronavirus disease 2019 (COVID-19) vaccination against severe COVID-19 illness faded in...

Study: Comparative immunogenicity of heterologous versus homologous 3rd SARS-CoV-2 vaccine doses in kidney transplant recipients. Image Credit: Wetzkaz Graphics / Shutterstock.com

Study shows homologous COVID boosters better than heterologous in most kidney transplant recipients

by Medical Finance
May 20, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers screen kidney transplant recipients to evaluate their serological responses following...

Next Post
Nutritional components hold promise for improving the health and well-being of adults

Molecular RNA profile of naked mole-rats reveals new insights on skin aging

Study: Anisodamine potently inhibits SARS-CoV-2 infection in vitro and targets its main protease. Image Credit: SKK Pix / Shutterstock

Compound found in Datura shows promise as antiviral agent against SARS-CoV-2

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • shutterstock 1495084595 1
    The Future of Microbiome Research
  • Girl in wheelchair 620x480
    Twin study identifies the influence of environment and genetics in multiple sclerosis
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply